LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 196

Search options

  1. Article ; Online: The scope for pneumococcal vaccines that do not prevent transmission.

    Flasche, Stefan

    Vaccine

    2017  Volume 35, Issue 45, Page(s) 6043–6046

    Abstract: The pneumococcal vaccine pipeline holds candidates developed with the aim to prevent the majority if not all pneumococcal disease. Herd protection is a critical component of the overall impact of current pneumococcal conjugate vaccines (PCVs) and is a ... ...

    Abstract The pneumococcal vaccine pipeline holds candidates developed with the aim to prevent the majority if not all pneumococcal disease. Herd protection is a critical component of the overall impact of current pneumococcal conjugate vaccines (PCVs) and is a prerequisite for disease elimination through an infant vaccination programme. We assessed the scope of a hypothetical pneumococcal vaccine candidate (HPVC) with high clinical efficacy against all pneumococci but that fails to induce such indirect protection. We found that, despite a lack of impact on unvaccinated individuals, HPVC use in infancy may offer similar or superior impact among young children if compared to current PCVs. Hence, it could provide a more affordable alternative to PCVs in particular in settings where most pneumococcal disease is concentrated in children.
    Language English
    Publishing date 2017-10-27
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.09.073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The role of schools and school-aged children in SARS-CoV-2 transmission.

    Flasche, Stefan / Edmunds, W John

    The Lancet. Infectious diseases

    2020  Volume 21, Issue 3, Page(s) 298–299

    MeSH term(s) Aged ; COVID-19 ; Child ; Cross-Sectional Studies ; Disease Outbreaks ; England ; Humans ; Prospective Studies ; SARS-CoV-2 ; Schools
    Language English
    Publishing date 2020-12-08
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(20)30927-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The scope for pneumococcal vaccines that do not prevent transmission

    Flasche, Stefan

    Vaccine. 2017 Oct. 27, v. 35

    2017  

    Abstract: The pneumococcal vaccine pipeline holds candidates developed with the aim to prevent the majority if not all pneumococcal disease. Herd protection is a critical component of the overall impact of current pneumococcal conjugate vaccines (PCVs) and is a ... ...

    Abstract The pneumococcal vaccine pipeline holds candidates developed with the aim to prevent the majority if not all pneumococcal disease. Herd protection is a critical component of the overall impact of current pneumococcal conjugate vaccines (PCVs) and is a prerequisite for disease elimination through an infant vaccination programme. We assessed the scope of a hypothetical pneumococcal vaccine candidate (HPVC) with high clinical efficacy against all pneumococci but that fails to induce such indirect protection. We found that, despite a lack of impact on unvaccinated individuals, HPVC use in infancy may offer similar or superior impact among young children if compared to current PCVs. Hence, it could provide a more affordable alternative to PCVs in particular in settings where most pneumococcal disease is concentrated in children.
    Keywords Streptococcus pneumoniae ; children ; disease eradication ; herd immunity ; infancy ; vaccination ; vaccines
    Language English
    Dates of publication 2017-1027
    Size p. 6043-6046.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2017.09.073
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  4. Article ; Online: Sensitivity and negative predictive value for a rapid dengue test.

    Flasche, Stefan / Smith, Peter G

    The Lancet. Infectious diseases

    2019  Volume 19, Issue 5, Page(s) 465–466

    MeSH term(s) Dengue ; Dengue Virus ; Humans ; Vaccination
    Language English
    Publishing date 2019-04-11
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(19)30167-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination.

    Hodgson, David / Wilkins, Neil / van Leeuwen, Edwin / Watson, Conall H / Crofts, Jonathan / Flasche, Stefan / Jit, Mark / Atkins, Katherine E

    The Lancet regional health. Europe

    2024  Volume 38, Page(s) 100829

    Abstract: Background: Two new products for preventing Respiratory Syncytial Virus (RSV) in young children have been licensed: a single-dose long-acting monoclonal antibody (la-mAB) and a maternal vaccine (MV). To facilitate the selection of new RSV intervention ... ...

    Abstract Background: Two new products for preventing Respiratory Syncytial Virus (RSV) in young children have been licensed: a single-dose long-acting monoclonal antibody (la-mAB) and a maternal vaccine (MV). To facilitate the selection of new RSV intervention programmes for large-scale implementation, this study provides an assessment to compare the costs of potential programmes with the health benefits accrued.
    Methods: Using an existing dynamic transmission model, we compared maternal vaccination to la-mAB therapy against RSV in England and Wales by calculating the impact and cost-effectiveness. We calibrated a statistical model to the efficacy trial data to accurately capture their immune waning and estimated the impact of seasonal and year-round programmes for la-mAB and MV programmes. Using these impact estimates, we identified the most cost-effective programme across pricing and delivery cost assumptions.
    Findings: For infants under six months old in England and Wales, a year-round MV programme with 60% coverage would avert 32% (95% CrI 22-41%) of RSV hospital admissions and a year-round la-mAB programme with 90% coverage would avert 57% (95% CrI 41-69%). The MV programme has additional health benefits for pregnant women, which account for 20% of the population-level health burden averted. A seasonal la-mAB programme could be cost-effective for up to £84 for purchasing and administration (CCPA) and a seasonal MV could be cost-effective for up to £80 CCPA.
    Interpretation: This modelling and cost-effectiveness analysis has shown that both the long-acting monoclonal antibodies and the maternal vaccine could substantially reduce the burden of RSV disease in the infant population. Our analysis has informed JCVI's recommendations for an RSV immunisation programme to protect newborns and infants.
    Funding: National Institute for Health Research.
    Language English
    Publishing date 2024-01-08
    Publishing country England
    Document type Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2023.100829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Vaccination to reduce antimicrobial resistance.

    Atkins, Katherine E / Flasche, Stefan

    The Lancet. Global health

    2018  Volume 6, Issue 3, Page(s) e252

    MeSH term(s) Anti-Infective Agents/pharmacology ; Anti-Infective Agents/therapeutic use ; Drug Resistance, Bacterial ; Humans ; Models, Theoretical ; Vaccination
    Chemical Substances Anti-Infective Agents
    Language English
    Publishing date 2018
    Publishing country England
    Document type Letter
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(18)30043-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The role of pneumococcal conjugate vaccination in reducing pneumonia mortality.

    Jit, Mark / Flasche, Stefan

    The Lancet. Global health

    2018  Volume 7, Issue 2, Page(s) e173–e174

    MeSH term(s) Brazil ; Child ; Humans ; Pneumococcal Vaccines ; Pneumonia ; Retrospective Studies ; Vaccination ; Vaccines, Conjugate
    Chemical Substances Pneumococcal Vaccines ; Vaccines, Conjugate
    Language English
    Publishing date 2018-12-20
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(18)30540-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Balancing Benefits and Risks of Antibiotic Use.

    Flasche, Stefan / Atkins, Katherine E

    The Journal of infectious diseases

    2018  Volume 218, Issue 9, Page(s) 1351–1353

    MeSH term(s) Anti-Bacterial Agents ; Anti-Infective Agents ; Humans ; Otitis Media ; Penicillins ; Risk Assessment ; Streptococcus pneumoniae
    Chemical Substances Anti-Bacterial Agents ; Anti-Infective Agents ; Penicillins
    Language English
    Publishing date 2018-08-10
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiy344
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study.

    Flasche, Stefan / Lipsitch, Marc / Ojal, John / Pinsent, Amy

    BMC medicine

    2020  Volume 18, Issue 1, Page(s) 129

    Abstract: Background: Herd protection through interruption of transmission has contributed greatly to the impact of pneumococcal conjugate vaccines (PCVs) and may enable the use of cost-saving reduced dose schedules. To aid PCV age targeting to achieve herd ... ...

    Abstract Background: Herd protection through interruption of transmission has contributed greatly to the impact of pneumococcal conjugate vaccines (PCVs) and may enable the use of cost-saving reduced dose schedules. To aid PCV age targeting to achieve herd protection, we estimated which population age groups contribute most to vaccine serotype (VT) pneumococcal transmission.
    Methods: We used transmission dynamic models to mirror pre-PCV epidemiology in England and Wales, Finland, Kilifi in Kenya and Nha Trang in Vietnam where data on carriage prevalence in infants, pre-school and school-aged children and adults as well as social contact patterns was available. We used Markov Chain Monte Carlo methods to fit the models and then extracted the per capita and population-based contribution of different age groups to VT transmission.
    Results: We estimated that in all settings, < 1-year-old infants cause very frequent secondary vaccine type pneumococcal infections per capita. However, 1-5-year-old children have the much higher contribution to the force of infection at 51% (28, 73), 40% (27, 59), 37% (28, 48) and 67% (41, 86) of the total infection pressure in E&W, Finland, Kilifi and Nha Trang, respectively. Unlike the other settings, school-aged children in Kilifi were the dominant source for VT infections with 42% (29, 54) of all infections caused. Similarly, we estimated that the main source of VT infections in infants are pre-school children and that in Kilifi 39% (28, 51) of VT infant infections stem from school-aged children whereas this was below 15% in the other settings.
    Conclusion: Vaccine protection of pre-school children is key for PCV herd immunity. However, in high transmission settings, school-aged children may substantially contribute to transmission and likely have waned much of their PCV protection under currently recommended schedules.
    MeSH term(s) Adolescent ; Adult ; Age Factors ; Child ; Child, Preschool ; Female ; Humans ; Immunity, Herd/immunology ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Models, Theoretical ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/administration & dosage ; Pneumococcal Vaccines/therapeutic use ; Vaccines, Conjugate/administration & dosage ; Vaccines, Conjugate/therapeutic use ; Young Adult
    Chemical Substances Pneumococcal Vaccines ; Vaccines, Conjugate
    Language English
    Publishing date 2020-06-10
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2131669-7
    ISSN 1741-7015 ; 1741-7015
    ISSN (online) 1741-7015
    ISSN 1741-7015
    DOI 10.1186/s12916-020-01601-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019.

    Liu, Yang / Funk, Sebastian / Flasche, Stefan

    Wellcome open research

    2020  Volume 5, Page(s) 58

    Abstract: Background: ...

    Abstract Background:
    Keywords covid19
    Language English
    Publishing date 2020-04-01
    Publishing country England
    Document type Journal Article
    ISSN 2398-502X
    ISSN 2398-502X
    DOI 10.12688/wellcomeopenres.15788.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top